KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
93 hedge funds and large institutions have $310M invested in KalVista Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 12 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 23
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
17% more capital invested
Capital invested by funds: $265M → $310M (+$45M)
6% more funds holding
Funds holding: 88 → 93 (+5)
2.14% more ownership
Funds ownership: 98.68% → 100.82% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
23% less call options, than puts
Call options by funds: $740K | Put options by funds: $959K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$7.02M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.62M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$2.68M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.7M |
| 5 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.6M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$1.89M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.87M |
| 4 |
JFG
Jefferies Financial Group
New York
|
-$1.57M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.44M |
KALV Hedge Fund Activity: Q2 2023 in Review
93 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2023, worth a combined $310M — up 17% from $265M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KALV positions and 12 closed out — a net gain of 5 holders — while 34 added to existing stakes and 23 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $7.02M. The largest seller was Great Point Partners, exiting entirely with an estimated $12.6M sold.
- 93 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2023, up from 88 in Q1 2023.
- Funds reported $310M of KalVista Pharmaceuticals stock for Q2 2023, up 17% quarter-over-quarter.
- 17 funds opened new KalVista Pharmaceuticals positions in Q2 2023 and 12 closed out, a net change of +5 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2023 was MPM BioImpact, an estimated $7.02M added.
- The largest KalVista Pharmaceuticals seller in Q2 2023 was Great Point Partners, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2023.